{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:26:33Z","timestamp":1790141193733,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,1]],"date-time":"2027-08-01T00:00:00Z","timestamp":1817078400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:16:10Z","timestamp":1781136970000},"page":"519-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Wei-Ying","family":"Jen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9542-1558","authenticated-orcid":false,"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-911X","authenticated-orcid":false,"given":"Issa","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10506","key":"10.1016\/j.clml.2026.06.002_bib0001","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.06.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.0613","article-title":"Management of adult acute lymphoblastic leukemia: a review","author":"Kantarjian","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.06.002_bib0003","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajh.27708","article-title":"Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2026.06.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35872","article-title":"The evolving therapeutic revolution in adult acute lymphoblastic leukemia","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"issue":"10299","key":"10.1016\/j.clml.2026.06.002_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2026.06.002_bib0006","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.06.002_bib0007","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.06.002_bib0008","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.06.002_bib0009","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.06.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.06.002_bib0011","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.06.002_bib0012","article-title":"ALL-774: safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: early results from the phase 1\/2 SYRUS study","volume":"25","author":"Aldoss","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2026.06.002_bib0013","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","article-title":"Dose-dense mini-hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab achieves rapid MRD-negativity in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"24","author":"Short","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.clml.2026.06.002_bib0014","article-title":"Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab","volume":"146","author":"Goulart","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.06.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70401","article-title":"Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia","volume":"132","author":"Kantarjian","year":"2026","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2026.06.002_bib0016","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600176X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502600176X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:19:41Z","timestamp":1785701981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502600176X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S215226502600176X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}